ALAMEDA, Calif., Aug. 23, 2023 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the following investor conferences on the dates and times listed below:
Event: | 2023 Wells Fargo Healthcare Conference |
Date: | Wednesday, September 6, 2023 |
Time: | 8:00am ET/5:00am PT |
Event: | Baird 2023 Global Healthcare Conference |
Date: | Tuesday, September 12, 2023 |
Time: | 2:00pm ET/11:00am PT |
Webcasts of the presentations will be available by visiting the investors' section of the company's website at www.penumbrainc.com. The webcasts will be available on the company's website for at least two weeks following the event.
About Penumbra
Penumbra, Inc., headquartered in Alameda, California, is a global healthcare company focused on innovative therapies. Penumbra designs, develops, manufactures and markets novel products and has a broad portfolio that addresses challenging medical conditions in markets with significant unmet need. Penumbra supports healthcare providers, hospitals and clinics in more than 100 countries. For more information, visit www.penumbrainc.com and connect on Twitter and LinkedIn.
Investor Relations
Penumbra, Inc.
510-995-2461
investors@penumbrainc.com
| Last Trade: | US$280.68 |
| Daily Change: | 5.36 1.95 |
| Daily Volume: | 700,334 |
| Market Cap: | US$10.770B |
April 23, 2025 February 18, 2025 December 30, 2024 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
